• Statements, pre-2008

in page functions
  • Access Gavi statements from pre-2008

  • 17 October 2007

    Malaria vaccine candidate has promising safety tolerability profile in infants

    At a forum today in Seattle, experts released the first study to test GlaxoSmithKline’s (GSK) investigational RTS, S/AS02D malaria vaccine in African infants. It serves as the first proof of concept in this population that the vaccine has a promising safety and tolerability profile and reduces malaria parasite infection and illness due to malaria, according to a paper published today online in The Lancet.

    26 September 2007

    The GAVI Fund’s Immunize Every Child Campaign announces its commitment to raise $30 million for pneumococcal vaccine

    The GAVI Fund’s Immunize Every Child Campaign, its new fund-raising initiative, has committed to raise $30 million for pneumococcal vaccine at this year’s Clinton Global Initiative (CGI). The Campaign will work with the CGI and other partners to raise $30 million in innovation capital for the Advance Market Commitment (AMC) for pneumococcal vaccine which protects against the leading infectious cause of child mortality worldwide. It will support the introduction and distribution of this, and other priority vaccines, to protect millions of children against life-threatening infectious diseases in the world’s 72 poorest countries.

    02 March 2006

    Statement by Julian Lob-Levyt at the Conference on Innovative Financing for Development

    GAVI congratulates France and the UK for their years of work invested in the search for creative new ways to pay for the measures that will be needed to meet the Millennium Development Goals.

close icon

modal window here